SCHEMBL5448281

SCHEMBL5448281

CCCCCCCC/C=C\CCCCCCCC(CC(O)CO)OC(CCCCCCC/C=C\CCCCCCCC)CC(O)CO

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DGKA P23743 1/20 0.50
ALDH1A1 P00352 2/20 0.45
CNR1 P21554 1/20 0.45
CNR2 P34972 1/20 0.45
FAAH O00519 2/20 0.45
FFAR1 O14842 1/20 0.44
FFAR4 Q5NUL3 1/20 0.44
MEN1 O00255 3/20 0.43
MAPT P10636 3/20 0.43
KMT2A Q03164 3/20 0.43
GMNN O75496 2/20 0.43
LMNA P02545 2/20 0.43
GLA P06280 2/20 0.43
POLB P06746 2/20 0.43
THRB P10828 2/20 0.43
CETP P11597 2/20 0.43
MAPK1 P28482 2/20 0.43
CXCR5 P32302 2/20 0.43
CCR6 P51684 2/20 0.43
BLM P54132 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14313850 0.96 DGKA (0.47) DGKAALDH1A1CNR1CNR2FAAH
SCHEMBL1782243 0.91 DGKA (0.46) DGKAALDH1A1CNR1CNR2FAAH
SCHEMBL9073956 0.90 USP2 (0.47) FFAR1FFAR4MEN1MAPTKMT2A
SCHEMBL17237503 0.90 USP2 (0.47) FFAR1FFAR4MEN1MAPTKMT2A
SCHEMBL17237494 0.90 USP2 (0.47) FFAR1FFAR4MEN1MAPTKMT2A
SCHEMBL17237492 0.90 USP2 (0.47) FFAR1FFAR4MEN1MAPTKMT2A
SCHEMBL11656416 0.88 USP2 (0.44) FFAR4MEN1MAPTKMT2AGMNN
SCHEMBL28862599 0.85 ALDH1A1 (0.56) DGKAALDH1A1CNR1CNR2FAAH
SCHEMBL28342030 0.85 DGKA (0.55) DGKAALDH1A1CNR1CNR2FAAH
SCHEMBL17237493 0.83 USP2 (0.41) ALDH1A1MEN1MAPTKMT2AGMNN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1670436-B1 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2013-11-20 EP claimed
US-20070231374-A1 Composition Comprising Ether Lipid CAMURUS AB (SE) 2007-10-04 US claimed
EP-1670436-A2 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2006-06-21 EP claimed
WO-2005027976-A2 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2005-03-31 WO claimed
EP-1670436-B1 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2013-11-20 EP disclosed
US-20070231374-A1 Composition Comprising Ether Lipid CAMURUS AB (SE) 2007-10-04 US disclosed
EP-1670436-A2 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2006-06-21 EP disclosed
WO-2005027976-A2 COMPOSITION COMPRISING ETHER LIPID CAMURUS AB (SE) 2005-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070231374-A1 Composition Comprising Ether Lipid ABHD16A, PHOSPHO1, LIPA DGKA 269/4885ALDH1A1 3376/4885CNR1 226/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.